NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as generic erosion of market leaders and increased competition between new hospital drugs will trigger a decline in sales of branded antibacterials. While there is a lack of innovation with regards to new community drugs, the hospital sector will remain the only notable source of growth.
Features and benefits
* Analysis of the antibacterials market across the US, Japan, France, Italy, Germany, Spain and the UK.
* Detailed ten-year sales forecasts for marketed antibacterial drugs in each of the seven major markets.
* Thorough assessments of key marketed antibacterial brands.
* Snapshot of market dynamics in the Rest of World.
In 2009, antibacterial sales in the seven major markets totalled $19.6bn, declining at a compound annual growth rate (CAGR) of -1.6% since 2005. This decline was largely caused by generic erosion of market-leading community brands, such as Zithromax and Klacid, combined with a paucity of new product launches.
Over the next decade, genericization of key brands will drive a significant decline in market value, contributing to a loss of revenues from Levaquin/Cravit/Tavanic, Zosyn/Tazocin, and Zyvox alone of $3.2bn by 2019. Combined with growing resistance, this will cause increasing market fragmentation and reduce the potential
Copyright©2010 PR Newswire.
All rights reserved